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background: Polycystic ovary syndrome (PCOS) is a common metabolic dysfunction and heterogeneous endocrine disorder in
women of reproductive age. Although patients with PCOS are typically characterized by increased numbers of oocytes retrieved during
IVF, they are often of poor quality, leading to lower fertilization, cleavage and implantation rates, and a higher miscarriage rate.
methods: For this review, we searched the database MEDLINE (1950 to January 2010) and Google for all full texts and/or abstract
articles published in English with content related to oocyte maturation and embryo developmental competence.
results: The search showed that alteration of many factors may directly or indirectly impair the competence of maturating oocytes
through endocrine and local paracrine/autocrine actions, resulting in a lower pregnancy rate in patients with PCOS. The extra-ovarian
factors identiﬁed included gonadotrophins, hyperandrogenemia and hyperinsulinemia, although intra-ovarian factors included members of
the epidermal, ﬁbroblast, insulin-like and neurotrophin families of growth factors, as well as the cytokines.
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Advanced Access publication on July 16, 2010 doi:10.1093/humupd/dmq032conclusions: Any abnormality in the extra- and/or intra-ovarian factors may negatively affect the granulosa cell–oocyte interaction,
oocyte maturation and potential embryonic developmental competence, contributing to unsuccessful outcomes for patients with PCOS who
are undergoing assisted reproduction.
Key words: polycystic ovary syndrome / oocyte / fertilization / embryo / IVF
Introduction
Polycystic ovary syndrome (PCOS) is a common metabolic dysfunc-
tion and heterogeneous endocrine disorder in women of reproductive
age (Franks, 1995, 2008; Knochenhauer et al., 1998; Diamanti-
Kandarakis et al., 2008; Asuncio ´n et al., 2000; Azziz, 2004; Wood
et al., 2007; Toulis et al., 2009). It is characterized by a clustering of
hyperandrogenism, hyperinsulinemia, hypersecretion of LH, menstrual
dysfunction, hirsutism, infertility and pregnancy and neonatal compli-
cations (Franks, 1995; Moran and Teede, 2009; Stubbs et al., 2007;
Toulis et al., 2009). Women with PCOS undergoing IVF treatment
have been well-described (Ludwig et al., 1999; Legro, 2001; Mulders
et al., 2003; Heijnen et al., 2006; Sahu et al., 2008). Although PCOS
patients are typically characterized by producing an increased
number of oocytes, they are often of poor quality, leading to lower
fertilization, cleavage and implantation rates, and a higher miscarriage
rate (Sengoku et al., 1997; Ludwig et al., 1999; Mulders et al., 2003;
Heijnen et al., 2006; Weghofer et al., 2007; Sahu et al., 2008;
Boomsma et al., 2008). This evidence raises the issue that poor
oocyte and embryo quality may contribute to increased aneuploidy
rates (Munne ´ et al., 1995; Gianaroli et al., 2003, 2007). However,
recent data suggest that women with PCOS yield higher numbers of
oocytes and produce more euploid embryos in IVF, but still result in
lower pregnancy and increased miscarriage rates, which are not
genetically associated with an increased risk for embryonic aneuploidy
(Weghofer et al., 2007). Hence, other factors, aside from chromoso-
mal factors, are most likely associated with the signiﬁcantly increased
risk for pregnancy loss in patients with PCOS (Sagle et al., 1988;
Carmina and Lobo, 1999; Wood et al., 2007; Weghofer et al.,
2007). Impaired oocyte maturation and embryonic developmental
competence in PCOS women is possibly linked with abnormal endo-
crine/paracrine factors, metabolic dysfunction and alterations in the
intrafollicular microenvironment during folliculogenesis and follicle
maturation (Franks et al., 2002; Dumestic et al., 2007b; Dumesic
and Abbott, 2008; Wood et al., 2007). Therefore, a better under-
standing of how PCOS is related to abnormalities in extra- and
intra-ovarian factor (Fig. 1, Table I) and their impact on granulosa
cell (GC)–oocyte interactions, oocyte maturation and potential
embryonic developmental competence, will be crucial to improving
fertility and optimizing clinical stimulation, thus enhancing pregnancy
outcomes in women with PCOS undergoing IVF treatment.
Methods
For this review, we searched the database MEDLINE (1950 to January
2010) and GOOGLE for all full texts and/or abstract articles published
in English; our own unpublished data were taken into account as well.
Search terms included ‘oocyte’, ‘embryo’, ‘oocyte and embryo’, ‘oocyte
and embryo quality’, ‘oocyte quality’, ‘embryo quality’, ‘fertilization’,
‘oocyte aneuploidy’, ‘embryo aneuploidy’, ‘oocyte abnormality’, ‘embryo
abnormality’, ‘clinical issue’, ‘laboratory issue’, ‘IVF outcome’, ‘follicle
ﬂuid’, ‘follicle ﬂuid hormone’, ‘follicle ﬂuid and oocyte’, ‘follicle ﬂuid and
embryo’, ‘folliculogenesis’, ‘extra- and intra-ovarian factors’, ‘follicular
ﬂuid factors’ and ‘growth factors’ in PCOS. This search resulted in 1596
papers. Upon screening the results for applicable titles and/or abstracts,
only articles correlating to PCOS and its relatives were selected for this
review. In addition, we hand-searched references of relevant reviews,
and conference abstracts, and included ongoing studies to locate other
potentially eligible materials.
Extra-ovarian factors
Human folliculogenesis and follicle maturation are complicated devel-
opmental processes through which a mature follicle is differentiated
from primordial follicles, yielding one mature follicle that is eventually
selected to ovulate, releasing a mature oocyte. This developmental
process can be disrupted by abnormal extra-ovarian endocrine
factors, resulting in ovarian dysfunction. Complex endocrine disorders,
such as FSH deﬁciency, hypersecretion of LH, hyperandrogenemia and
hyperinsulinemia with insulin resistance, are responsible for the patho-
genesis of PCOS, consequently increasing the risks of impaired oocyte
developmental competence, implantation failure and miscarriage (Van
der Spuy and Dyer, 2004; Dumesic et al., 2007a; Dumesic and Abbott,
2008; Boomsma et al., 2008).
FSH deﬁciency
FSH stimulates follicular growth and recruitment of immature follicles
from the ovary. FSH is the major survival factor during folliculogenesis,
when there is a delicate balance between recruitment and atresia of
follicles. Human antral follicles between 2 and 5 mm become respon-
sive to FSH, whereas slightly larger follicles between 6 and 8 mm
acquire aromatase activity and potentially increase the estradiol (E2)
levels (Dumesic and Abbott, 2008). With the concomitant rise in E2
and inhibin B, FSH levels then decline in the late follicular phase, and
eventually only the most advanced and mature follicle is selected to
proceed to ovulation. At the end of the luteal phase, there is a
slight rise in the FSH level, which is very important in initiating the
next ovulatory cycle (Erickson and Shimasaki, 2001; Padhy et al.,
2009). In contrast, PCOS patients show lower serum FSH levels as
compared with normal cycles (Hillier, 1994). Consequently, FSH
deﬁciency results in an increased accumulation of antral follicles
between 2 and 8 mm (Franks et al., 2000, 2008). Clearly, the high
number of smaller follicles indicates many have undergone premature
arrest and failed to become the dominant follicle (Franks et al., 2008;
Padhy et al., 2009). However, the developmental competence of
oocytes collected from women with PCOS is normal, potentially
leading to similar fertilization and normal cumulative pregnancy rates
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Heijnen et al., 2006; Franks et al., 2008).
PCOS patients undergoing IVF commonly demonstrate elevated E2
levels, combined with a signiﬁcantly higher number of oocytes
retrieved, lower number of high-quality oocytes, poor fertilization
rates, increased embryonic fragmentation, decreased percentage of
blastocyst formation and lower impanation rates (Cano et al.,
1997a, b; Urman et al., 2004). High E2 levels in PCOS patients may
be detrimental to oocyte maturation and embryonic development
(Hardy et al., 1995). In addition, recovery of immature oocytes fol-
lowed by in vitro maturation (IVM) is a potentially useful treatment
option for women with PCOS-related infertility. As an alternative
approach, minimal or mild ovarian stimulation with FSH before
oocyte collection has been applied in PCOS patients (Chian, 2004).
Immature oocytes are then cultured in complex IVM culture
medium plus 75 mIU/ml FSH + LH 75 mIU/ml for 24–48 h. ICSI is
performed for mature oocytes. Despite the elevated number of imma-
ture oocytes obtained from PCOS patients with declining serum FSH
levels (Dumesic et al., 2007b; Franks et al., 2008), oocyte maturation
in vitro induced by extrinsic FSH and cumulus cell (CC)–oocyte inter-
actions are crucial for the acquisition of oocyte developmental poten-
tial (Wynn et al., 1998; Dumesic et al., 2007b). Consequently, oocytes
become fertilized embryos and potentially develop into the blastocyst
stage (De La Fuente, 2006; Dumesic et al., 2007b). Results suggest
that the cumulative pregnancy rate by IVM treatment in women
with PCOS is comparable with that of other PCOS women under-
going conventional IVF (Child et al., 2001; Cha et al., 2005;
So ¨derstro ¨m-Anttila et al., 2005). However, recent studies have
suggested that IVM has deleterious effects on the spindle organization
and chromosomal conﬁguration of oocytes from PCOS patients
(Li et al., 2006; Navarro et al., 2007, 2009; Nichols et al., 2010), poss-
ibly explaining the reduced developmental competence of oocytes
matured in vitro, compared with those matured in vivo. This may poss-
ibly contribute to the decline in the overall clinical outcome observed
after IVM treatment (Li et al., 2006; Navarro et al., 2007, 2009).
Hypersecretion of LH
Women with PCOS typically have tonic hypersecreton of LH during
the follicular phase of their cycles (Balen et al., 1993; Cano et al.,
1997a, b; van der Spuy and Dyer, 2004). High LH levels have been
associated with signiﬁcant decreases in oocyte maturation and fertiliza-
tion rates, and impaired embryo quality, consequently resulting in
impaired pregnancy rates, and higher miscarriage rates (Adams
et al., 1985; Stanger and Yovich, 1985; Hombur and Jacobs, 1989;
Regan et al., 1990; Sengoku et al., 1997; Ludwig et al., 1999; Jabara
and Coutifaris, 2003; Urman et al., 2004; van der Spuy and Dyer,
2004; Santos et al., 2010). Hyperseceretion of LH during folliculogen-
esis may suppress FSH function, resulting in abnormal GC function by
promoting premature GC luteinization and follicular aresia in small
antral follicles from women with PCOS, causing premature oocyte
maturation via inhibition of oocyte maturation inhibitors (Tesarik,
2003; van der Spuy and Dyer, 2004; Dumesic et al., 2007b; Franks
et al., 2008), which all impair the quality of both oocyte and
embryo (Tarlatzis and Grimbizis, 1997; Dumesic et al., 2002). LH
may also activate premature meiotic processes by damaging the
oocyte nucleus, leading to apoptosis via a receptor-coupled signal
transduction system (Yoshimura and Wallach, 1987; Kurzawa et al.,
2008). Disruption of the endocrine control of meiosis, resulting in
impaired extrusion of the ﬁrst polar body, may compromise the
Figure 1 Intra-and extra-ovarian factors associated with the PCOS pathology that negatively affect oocyte and subsequent embryo quality.
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Table I Factors in serum and follicular ﬂuid of patients with PCOS: impact on quality of oocyte and embryo, fertilization
and outcome of pregnancy.
Factors Serum
level
FF
level
Oocyte
quality
Fertilization
rate
Embryo
quality
Pregnancy
rate
References
Activin    Norman et al. (2001), Erickson
et al. (1995)
Anti-Mu ¨llerian hormone      or    or ≈ or    or ≈  or ≈ Fallat et al. (1997), Wang et al.
(2007a, b), Mashiach et al. (2010),
Desforges-Bullet et al. (2010)
Epidermal growth factor   Volpe et al. (1991), Almahbobi
et al. (1998), Artini et al. (2007)
Fibroblast growth factor   or    or  ≈ or  ≈ ≈ Hammadeh et al. (2003), Artini
et al. (2006)
Follistatin    Erickson et al. (1995), Norman
et al. (2001), Eldar-Geva et al.
(2001)
Brain-derived neurotrophic
factor
  Johnstone et al. (2008), Buyuk and
Seifer (2008)
Bone morphogenetic
protein-15
       Wu et al. (2007a, b)
Estradiol          Berker et al. (2009), Amato et al.
(2003)
Follicular ﬂuid
meiosis-activating sterol
   ≈ ≈ Bokal et al. (2006)
Growth differentiation
factor-9
   Zhao et al. (2010)
Homocysteine          Naﬁye et al. (2010), Berker et al.
(2009)
Insulin-like growth
factor-1 & 2
     Schoyer et al. (2007), Barreca et al.
(1996), Eden et al. (1988)
IGF binding proteins      Cataldo and Giudice (1992),
Schoyer et al. (2007)
Interleukin 12        Gallinelli et al. (2003)
Interleukin 13        Gallinelli et al. (2003)
Inhibin A&B   or ≈≈ Welt et al. (2005), Magofﬁn and
Jakimiuk (1998)
Corticotrophin-releasing
hormone
   Mastorakos et al. (1994)
Leptin            Mantzoros et al. (2000), Georgios
et al. (2005), Li et al. (2007)
Leukemia inhibitory factor          Le ´de ´e-Bataille et al. (2001)
Malondialdehyde          Yildirim et al. (2007), Berker et al.
(2009), Chattopadhayay et al.
(2010)
Matrix metalloproteinase
2/9
  or ≈ Shalev et al. (2001), Lahav-Bratz
et al. (2003)
Nerve growth factor   or   Dissen et al. (2009); Buyuk and
Seifer (2008)
Renin          Bokal et al. (2003, 2004, 2005)
Resistin ≈≈ ≈ ≈ ≈ Seow et al. (2005), Lu et al. (2005)
Reactive oxygen species          Chattopadhayay et al. (2010),
Samanta et al. (2008)
Soluble Fas      Onalan et al. (2005)
sFas Ligand      Onalan et al. (2005)
Continued
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contributing to embryonic aneuploidy in women with PCOS
(Weghofer et al., 2007). Errors in embryogenesis stemming from
abnormal and premature oocyte exposure to increased LH stimulation
may explain the elevated miscarriage rate in PCOS patients (Balen
et al., 1993; Urman et al., 2004).
Hyperandrogenemia
Hyperandrogenemia is a common disorder in PCOS; it is mutifactorial
in origin, typically attributed to the ovary with substantial contributions
from an adrenal source, and to a lesser extent adipose tissues (van der
Spuy and Dyer, 2004; Nisenblat and Norman, 2009). Elevated free cir-
culating levels of bioactive androgen results from either direct
increases of ovarian production or an inhibition of hepatic synthesis
of sex hormone-binding globin in PCOS patients with insulin resistance
(Balen et al., 1995; van der Spuy and Dyer, 2004; Nisenblat and
Norman, 2009). Increased androgen concentrations in the follicular
ﬂuid (FF) are associated with elevated serum LH levels, which may
block dominant follicle development and cause follicular arrest and
degeneration (Billig et al., 1993; Kurzawa et al., 2008). It has been
suggested that high levels of androgen may have a negative impact
on oocyte developmental competence (Brzynski et al., 1995; Teissier
et al., 2000; Jabara and Coutifaris, 2003). Incubation of the oocyte with
androgen in vitro is associated with decreased oocyte maturation rates
(Tesarik and Mendoza, 1995). Data from an in vitro model suggest that
testosterone exerts a strong inhibition of meiotic maturation and
embryonic development in CC-free mouse oocytes, compared with
CC-enclosed oocytes; this demonstrates that CCs can protect
oocytes via local aromatase activity in human (Laufer et al., 1984;
Dumesic et al., 2007b) and mice (Anderiesz and Trounson, 1995).
Such a CC function plays an important role in PCOS folliculogenesis,
since small PCOS follicles are hyperandrogenic (Eden et al., 1990;
Dumesic et al., 2007b) owing to intrinsically raised androgen biosyn-
thesis by theca cells (Nelson et al., 2001). Further studies have
suggested that elevated testosterone, either directly or indirectly,
decreases the rates of IVM, fertilization and embryonic development
(Dumesic et al., 2007b; Patel and Carr, 2008). The mechanism of
testosterone activity within the oocyte may be related to decreased
calcium oscillations, consequently inhibiting oocyte cytoplasmic matu-
ration, with effects on meiotic maturation (Tesarik and Mendoza,
1995, 1997; Jabara and Coutifaris, 2003). In addition, elevated testos-
terone concentrations are associated with higher miscarriage rates in
women with PCOS (van der Spuy and Dyer, 2004), suggesting that
androgens may have a detrimental effect on folliculogenesis and endo-
metrial function (Okon et al., 1998; Tuckerman et al., 2000).
Hyperinsulinemia
PCOS is an endocrine–metabolic disorder, closely tied to insulin
resistance and a compensatory hyperinsulinemia. Metformin is the
drug which has been studied most, and is administered to reduce
fasting insulin, LH and free testosterone level, in an effort to restore
menstrual cyclicity and fertility (Tang et al., 2010). It has been reported
that insulin resistance is related to an increased miscarriage rate (Craig
et al., 2002); several studies have suggested that metformin can effec-
tively reduce pregnancy loss in women with PCOS (Glueck et al.,
2001; Jakubowicz et al., 2002; Kjotrod et al., 2004; Galal and Mitwally,
2009). Hyperinsulinemia may have preferentially impaired oocyte
developmental competence, resulting in reduced rates of fertilization,
embryonic development and implantation in PCOS patients with
obesity (Hamilton-Fairley et al., 1992; Cano et al., 1997a, b; Wang
et al., 2001; Wijeyaratne et al., 2002; Jabara and Coutifaris, 2003;
Dumesic et al., 2002, 2007b; Dumesic and Abbott, 2008; Palep-Singh
et al., 2007; Tian et al., 2007; Boomsma et al., 2008). Data from in vitro
cell culture models suggest that co-incubation of insulin and FSH with
mouse (Eppig et al., 1998) and bovine (Galal and Mitwally, 2009)
oocytes promotes FSH-induced up-regulation of GC LH receptor
mRNA expression (Dumesic et al., 2002; Tao and Yan, 2005;
Diamanti-Kandarakis, 2008), inhibiting FSH stimulation of aromatase
activity (Galal and Mitwally, 2009), thus reducing the percentage of fer-
tilized oocytes that develop into blastocysts (Eppig et al., 1998;
Dumesic et al., 2002, 2007b). Insulin may induce local androgen pro-
duction, which results in oocytes of lower quality, post-maturity (Cano
et al., 1997a, b). At the molecular level, insulin binds to its receptor,
localized on GC and theca cells, and oocytes, to stimulate follicle
.............................................................................................................................................................................................
Table I Continued
Factors Serum
level
FF
level
Oocyte
quality
Fertilization
rate
Embryo
quality
Pregnancy
rate
References
Superoxide dismutase   or ≈  or ≈ Sabatini et al. (2000), Bausenwein
et al. (2010)
Total antioxidant capacity            Chattopadhayay et al. (2010)
Testosterone      Brzynski et al. (1995), Teissier et al.
(2000)
Tissue inhibitor of
metalloproteinase-1 & 2
  or ≈ Lahav-Bratz et al. (2003), Shalev
et al. (2001)
Tumor necrosis factor a            Amato et al. (2003), Wu et al.
(2007a, b), Kim et al. (2009)
Vascular endothelial growth
factor
  or    or      or ≈    Bokal et al. (2004, 2005, 2009),
Artini et al. (2006, 2009)
Visfatin  ≈ Plati et al. (2009)
All data are as compared with controls (patients without PCOS). , increases or positive impact;  , decreases or negative impact; ≈, similar; blank, no data.
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quently altering expression of multiple genes involved in meiotic/
mitotic spindle dynamics and centrosome function in PCOS ooctyes
(Wood et al., 2007). This indicates that insulin may be an important
mediator of oocyte developmental competence via a ligand-receptor
regulating system (Dumesic et al., 2007b).
Intra-ovarian factors
Ovarian folliculogenesis is regulated by a ﬁne balance between extra
and intra-ovarian factors (Artini et al., 2007). Oogenesis is profoundly
dependent upon intra-ovarian factors, in particular follicle ﬂuid factors
(FFFs) (Andreani et al., 1996; Hsieh et al., 2009; Padhy et al., 2009),
which are positively related to levels of these factors in serum
(Table I). Any imbalance or dysfunction between extra- and
intra-ovarian factors may result in abnormal folliculogenesis and
oogenesis disorder (Frank et al., 2002, 2008; Artini et al., 2007).
Recent studies suggest that the main FFFs implicated in polycystic
ovary folliculogenesis are members of the growth factor families, cyto-
kines, inhibins and others (Franks et al., 2002; Artini et al., 2007;
Diamanti-Kandarakis, 2008). Furthermore, a series of different
serum factors, coupled with the intrafollicular ﬂuid microenvironment,
may directly impair oocyte developmental competence, should their
balance be altered (Yen et al., 1993; Andreani et al., 1996; van der
Spuy and Dyer, 2004; Artini et al., 2007; Padhy et al., 2009); this
would consequently have a negative impact on the fertilization,
embryonic development and outcome of pregnancy in PCOS patients
(Table I and Fig. 1).
Epidermal growth factor family
Epidermal growth factor (EGF) is a soluble growth factor that plays an
important role in the regulation of cell growth, proliferation and differ-
entiation when bound to its receptor, EGFR (ErbB1, ErbB2-4; Hsieh
et al., 2009). In the human ovary, EGF is found in the FF, regulating fol-
licular development and oocyte meiotic maturation competence via
EGFR signaling transduction system in the CCs (Westergaard and
Andersen, 1989; Almahbobi et al., 1998; Jamnongjit et al., 2005;
Hsieh et al., 2009). IVM studies show that exposure of the
cumulus–oocyte complex (COC) to EGF stimulates CC expansion
and improves the nuclear and cytoplasmic maturation of oocytes
from the metaphase I (MI) to metaphase II (MII) stage in both
humans and other mammals (Goud et al., 1998; Smitz et al., 1998;
De La Fuente et al., 1999), signiﬁcantly facilitating fertilization and
embryo development (Singh et al., 1997; Goff et al., 2001). Other
studies suggest that FF EGF levels have an inverse correlation with
oocyte maturation (Hofmann et al., 1990; Das et al., 1992; Ozornek
et al., 1999; Hsieh et al., 2009). In women with PCOS, FF EGF
levels are higher than those of normally ovulating women (NOW),
which may suggest the involvement of EGF in the maintenance of
PCOS (Volpe et al., 1991; Artini et al., 2007). EGF inhibits estrogen
synthesis in GCs, which may explain why EGF blocks antral follicle
growth and results in follicular arrest in PCOS patients (Artini et al.,
2007). Therefore, it is hypothesized that a disruption in the regulatory
mechanisms of EGF synthesis and/or physiological function mediated
by EGFR may cause anovulatory infertility in women with PCOS
(Almahbobi and Trounson, 1996; Almahbobi et al., 1998). Whether
an elevated level of EGF in FF is correlated to oocyte quality and
embryonic developmental competence is still unclear.
In addition, EGF-like factors, such as amphiregulin, epiregulin and
betacellulin, are reportedly involved in oocyte maturation through
autocrine and paracrine mechanisms (Ashkenazi et al., 2005;
Shimada et al., 2006; Tse and Ge, 2009); however, the physiological
function of EGF-like factors in PCOS remains unknown.
Fibroblast growth factor family
Fibroblast growth factors (FGFs) are a group of polypeptides that play
a fundamental role in development, cell growth, tissue repair and
transformation (Hammadeh et al., 2003). They are expressed in GC
and theca cells of growing follicles, and are considered to be physio-
logical regulators of FSH action (Artini et al., 2006, 2007); this may
suggest a role for FGF in oocyte maturation by affecting surrounding
follicular GC and theca cells (Skinner, 2005; Artini et al., 2007). A pre-
vious study shows that FGF levels in the serum and FF are lower in
PCOS patients in comparison to patients with endometriosis and
tubal factors (Hammadeh et al., 2003). In contrast, another research
group reported that FGF concentrations are increased in the FF and
serum of PCOS patients when compared with controls, leading to
an inverse correlation with oocyte maturity (Artini et al., 2006,
2007): this supports speculation that FGF contributes to alterations
in the intra-follicle environment, resulting in arrest of follicle develop-
ment in patients with PCOS (Artini et al., 2007). Therefore, FGF
alterations in the FF and serum remain controversial; the impact of
EGF on oocyte maturation and embryonic development requires
further elucidation in PCOS patients.
Insulin-like growth factor family
Insulin-like growth factors (IGFs) are multifunctional polypeptides with
insulin-likeactivity.IGFsarepartofacomplexsystemusedbycellstocom-
municatewiththeirphysiologicalenvironment.Thiscomplexsystemcon-
sists of two surface-receptors (IGF1R and IGF2R), two receptor ligands
(IGF-I and IGF-II), six high-afﬁnity IGF binding proteins (IGFBP 1-6) and
their speciﬁc proteases (Adashi, 1993; Frattali and Pessin, 1993; Yen
et al., 1993; Erickson and Shimasaki, 2001; Artini et al., 2007).
Insulin-like growth factor-I/II and IGF binding proteins
IGFs and their binding proteins, IGFBPs, have important regulatory
functions in ovarian follicular development (Yen et al., 1993; Artini
et al., 2007). Circulating IGFs are produced in the liver, local IGF-I is
secreted by theca cells whereas IGF-II is synthesized by GCs, and
IGFBPs are present in the FF and expressed by GCs and theca cells
(Yen et al., 1993; Erickson and Shimasaki, 2001; Artini et al., 2007).
Although how IGFs are involved in the pathogenesis of PCOS
remains unknown, the excess insulin concentrations and alterations
in IGFs expression may be implicated (Yen et al., 1993). One recent
report suggests that the FF IGF-I levels in PCOS women are elevated,
although IGF-II and IGFBP-1 levels are lower than NOW (Artini et al.,
2007). However, FF IGFBP-2 and -4 levels are signiﬁcantly greater
(Yen et al., 1993; Kwintkiewicz and Giudice, 2009); in contrast,
IGFBP-1 is lower in PCOS patients, leading to follicular arrest (Artini
et al., 2007). This evidence suggests that an altered IGF system is
directly correlated to the oligo-ovulatory disorder of PCOS women
(Kwintkiewicz and Giudice, 2009).
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IGF-I levels (Amato et al., 1999). Research shows the levels of IGF-I,
IGF-II and IGFBP-3 in mature follicles to be comparable between
PCOS patients and controls; however, IGF-I levels in immature follicles
in PCOS patients is decreased during ovarian stimulation, and this is
associated with the generation of immature oocytes (Eden et al.,
1988; Rabinovici et al., 1990; Franchimont et al., 1994; Pellegrini
et al., 1995; Barreca et al., 1996; Dragisic et al., 2006; Schoyer
et al., 2007), At the same time, IGFBP-3 levels are increased during
stimulation, resulting in a greater likelihood of achieving pregnancy in
PCOS patients (Schoyer et al., 2007). In infertile IVF patients, the
ratio of IGF-1/IGFBP-1 in the serum and FF is signiﬁcantly increased
in women who become pregnant, highlighting the importance of
oocyte quality and maturity during ovarian stimulation for IVF
(Jimena et al., 1992; Artini et al., 1994; Kawano et al., 1997;
Oosterhuis et al., 1998; Fried et al., 2003). Furthermore, results
from in vitro culture models demonstrate that IGF-I can signiﬁcantly
increase embryonic development and blastocyst formation (Lighten
et al., 1998; Liu et al., 1999; Fried et al., 2003). Hence, study of FF
proteins may help to elucidate the roles of IGFs in GC function,
meiotic maturity, oocyte chromosomal normality and embryonic
developmental competence in PCOS patients.
Neurotrophin growth factor family
Brain-derived neurotrophic factor (BDNF), nerve growth factor
(NGF), NT-3 and NT-4/5 are major members of the neurotrophin
(NT) family of growth factors that are involved in development of
the central and peripheral nervous systems (Levi-Montalcini, 1987;
Snider, 1994; Buyuk and Seifer, 2008). NTs are not only involved in
the nervous system, but also act on the ovaries of humans and
other mammals (Seifer et al., 2002a, b, 2003; Buyuk and Seifer,
2008). NTs play a fundamental role in folliculogenesis and cytoplasmic
competence of the oocyte (Buyuk and Seifer, 2008). Data from
research using in vitro animal models suggest that co-incubation with
BDNF promotes nuclear and cytoplasmic maturation of the oocyte,
which are essential processes for successful oocyte and preimplanta-
tion embryo development (Da Silva et al., 2005; Kawamura et al.,
2005). Evidence from some studies shows that increased FF BDNF
and NGF levels are closely related to the pathology of women with
PCOS (Bai et al., 2004; Johnstone et al., 2008; Dissen et al., 2009).
Another report found that FF BDNF and NT-3 levels are increased,
but FF NGF is decreased, in women with PCOS (Buyuk and Seifer,
2008) which may be indicative of the differential status of follicles in
PCOS patients. Therefore, NT mechanisms in POCS pathogenesis,
especially their impact on oocyte and embryo developmental compe-
tence, need further clariﬁcation at different stages of follicle
development.
Transforming growth factor-b family
Among the many intra-ovarian factors, particular members of the
transforming growth factor (TGF)-b family play an important biological
role in follicle growth and oocyte development. These family members
include anti-Mu ¨llerian hormone (AMH)/Mu ¨llerian inhibiting substance
(MIS), activin, follistatin, inhibins, bone morphogenetic protein
(BMP)-9 and growth differentiation factor (GDF)-9 (PieK et al.,
1999; Artini et al., 2007; Dumesic et al., 2007b; Dumesic and
Abbott, 2008). Under different physiological conditions, TGF-b
family members may either promote or block ovarian follicle growth
and/or differentiation of the GC–oocyte complex, which is also
related to the pathogenesis of PCOS (van der Spuy and Dyer, 2004;
Diamanti-Kandarakis, 2008; Dumesic and Abbott, 2008).
Anti-Mu ¨llerian hormone/Mu ¨llerian inhibiting substance
AMH, also known as Mu ¨llerian inhibiting factor (MIF), Mu ¨llerian inhibit-
ing hormone (MIH) or MIS, is a homodimeric glycoprotein with a mol-
ecular weight of 140 kDa (Di Clemente et al., 2003; Artini et al.,
2007). It inhibits the development of the Mu ¨llerian ducts in the male
embryo (Behringer, 1994). AMH is expressed by GCs within ovaries
of women of reproductive age, controlling the formation of primary
follicles by inhibiting excessive follicular recruitment by FSH and there-
fore plays an important role in folliculogenesis (Weenen et al., 2004;
Sadeu and Smitz, 2008). Some studies have demonstrated that
AMH levels reﬂect some aspects of ovarian function, making AMH
levels a potential marker for assessing conditions such as PCOS and
premature ovarian failure (Visser et al., 2006; Sir-Petermann and
King, 2007; Diamanti-Kandarakis, 2008; Dumesic and Abbott, 2008;
Marca et al., 2009). Women with PCOS have elevated serum and
FF AMH levels versus those of normal controls (Pigny et al., 2003;
Laven et al., 2004; Artini et al., 2007), which is closely associated
with increased development of antral follicles and follicular arrest in
PCOS patients (Artini et al., 2007; Das et al., 2008; Diamanti-
Kandarakis, 2008; Franks et al., 2008). Elevated AMH serum levels
are directly correlated with increased testosterone and/or LH levels
in women with PCOS, and profoundly impairing oocyte developmen-
tal competence and embryo quality (Tarlatzis and Grimbizis, 1997;
Dumesic et al., 2002, 2007b; Patel and Carr, 2008; Franks et al.,
2008). Also, elevated FF AMH concentrations in women with PCOS
are linked to an increased percentage of immature oocyte and
lower fertilization rates when compared with women with endome-
triosis or pelvic adhesions (Fallat et a., 1997); this is supported by evi-
dence from the rat model as well (Takahashi et al., 1986). Recent
complementary investigation suggests that increased FF AMH in
women with PCOS may have harmful consequences on oocyte
quality and maturation, via an unclear molecular mechanism, but
does not have an effect on pregnancy rates (Desforges-Bullet et al.,
2010).
In a contrasting study conducted among women with PCOS, results
suggest that fertilization, implantation and clinical pregnancy rates are
signiﬁcantly better in the group with the highest FF AMH concen-
tration than in any group with a lower concentration (Pabuccu et al.,
2009). Additional reports reveal that women with PCOS who have
lower FF AMH levels have similar rates of oocyte maturation, fertiliza-
tion and embryonic development compared with NOW (Wang et al.,
2007a, b; Mashiach et al., 2010). However, recent evidence suggests
that FF AMH concentrations are only strongly and positively associated
with oocyte quality and implantation rates, but not rates of oocyte fer-
tilization, embryo cleavage and embryo morphology in NOW (Ebner
et al., 2006; Fanchin et al., 2007; Marca et al., 2009). Still, others
demonstrate that lower AMH levels are associated with poor
oocyte quality, as supported by decreased fertilization and embryonic
developmental rates, and increased miscarriage rates in IVF patients
(Lekamge et al., 2007) Therefore, AMH may directly affect cyto-
plasmic maturation of the oocytes. Based upon all of the above
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conditions during follicle development and oocyte maturation. Hence,
AMH may not be a valuable predictor for success in NOW and
women with PCOS undergoing assisted reproduction.
Activin, follistatin and inhibin
The activins, follistatin (FS) and inhibins are polypeptides which were
originally isolated and characterized from ovarian FF. FS is an
activin/inhibin binding protein produced by ovarian GCs, believed to
act in an autocrine/paracrine manner to regulate growth and differen-
tiation (Shimonaka et al., 1991; Findlay, 1993; Erickson et al., 1995);
over-expression of FS has been associated with increased arrest of fol-
licular development and decreased oocyte developmental compe-
tence (Erickson et al., 1995; Norman et al., 2001). Activins are
preferentially secreted by these smaller follicles, promoting follicular
development by increasing the GC response to FSH stimulation,
decreasing androgen synthesis and enhancing oocyte maturation. Inhi-
bins on the other hand, are produced by the dominant follicle and
stimulate theca cell androgen production for E2 synthesis (Schwall
et al., 1990; Klein et al., 2000; Knight and Glister, 2001; Dumesic
et al., 2007b). In NOW, studies suggest that FF levels of inhibin A,
inhibin B and activin A reﬂect changes in follicle size, but are not inde-
pendent markers of the oocyte’s ability to achieve fertilization and
pregnancy (Fried et al., 2003; Wen et al., 2006).
An early study failed to demonstrate any correlation between
inhibin A and B concentration in the FF and oocyte quality and fertili-
zation rates (Lau et al., 1999). IVF patients with high FF inhibin A and B
levels, measured on the day of oocyte retrieval, have better oocyte
maturity and fertilization rates, and higher pregnancy rates (Dzik
et al., 2000; Ocal et al., 2004). Another study reported that inhibin
B levels in the FF are signiﬁcantly correlated to embryo quality, but
not oocyte quality (Change et al., 2002). Interestingly, no differences
were found in the levels of FS and activin A in the FF from normal,
atretic or polycystic ovaries (Erickson et al., 1995).
Increased FS/activin ratios (high FS and low activin A) are well-
known contributors to the pathophysiology of PCOS (Eldar-Geva
et al., 2001; Norman et al., 2001); both proteins have an effect on
oocyte maturity and developmental competence, with activin enhan-
cing post-fertilization development, and FS blocking this function
(Norman et al., 2001). Elevated inhibin B levels are closely related
to an elevated risk of developing PCOS (Magofﬁn and Jakimiuk,
1997; Anderson et al., 1998; Lockwood et al., 1998). In addition,
studies have shown that inhibin A and B levels are signiﬁcantly
reduced in the FF of women with PCOS, when compared with FF
levels of size-matched follicles from NOW (Lambert-Meserlian
et al., 1997; Welt et al., 2005). Therefore, activin, FS and inhibins
bring about intra-ovarian actions through paracrine/autocrine
systems, playing an important role in maintaining folliculogenesis;
their imbalance may be directly correlated to the pathogenesis of
PCOS, consequently impairing oocyte maturity, embryo quality and
pregnancy outcome.
Growth differentiation factor-9 and bone morphogenetic protein-15
GDF-9 and BMP-15 (also called as GDF-9b) are two closely related
members of the TGF-b family of proteins and are highly expressed
in growing and full grown oocytes (Teixeira Filho et al., 2002; Gilchrist
et al., 2008; Chen et al., 2009). BMP-15 and GDF-9 play fundamental
roles in regulating CC functions through the processes of mitosis, pro-
liferation, apoptosis, luteinization, metabolism and expansion through
mitogenic signaling transduction mechanisms (Erickson and Shimasaki,
2001; Teixeira Filho et al., 2002; van der Spuy and Dyer, 2004;
Gilchrist et al., 2008; Chen et al., 2009). Data from in vitro models
demonstrate that co-incubation of COC with either BMP-15 or
GDF-9 substantially promotes oocyte maturation and enhances blasto-
cyt production, as well as increases the total number of cells in the tro-
phectoderm (Hussein et al., 2006) and inner cell mass of mouse
embryos (Yeo et al., 2008). Following embryo transfer in mice, the
rate of fetal survival almost doubles after exposure to BMP-15 or
GDF-9, but no differences could be detected in implantation rates
(Yeo et al., 2008). Importantly, both GDF-9 and BMP-15 are required
for folliculogenesis in humans and their abnormal expression may be
related to female infertility (Juengel et al., 2002; Teixeira Filho et al.,
2002; Shimasaki et al., 2004; Artini et al., 2007; Wu et al., 2007a, b;
Gilchrist et al., 2008), including increased correlations with PCOS path-
ologies (Franks et al., 2002; Teixeira Filho et al., 2002; van der Spuy and
Dyer, 2004; Ciepiela et al., 2007; Dumesic et al., 2007b, Dumesic and
Abbott, 2008; Gilchrist et al., 2008; Zhao et al., 2010). In infertile
women, elevated FF BMP-15 levels are positively correlated with
improved oocyte quality and higher rates of fertilization and embryonic
development, suggesting that BMP-15 may be a good indicator of
oocyte maturity and fertilization ability (Wu et al., 2007a, b). A recent
study demonstrates that the expression of GDF-9 and BMP-15
tended to be higher in PCOS patients when compared with a control
group, and thus may be involved in PCOS follicular dysplasia (Zhao
et al., 2010). GDF-9 expression in CCs is lower in PCOS patients,
which maylead toprematureluteinization and decreased oocyte devel-
opmental competence and luteal generation (Takebayashi et al., 2000;
Artini et al., 2007): this may also be correlated to elevated miscarriage
rates in women with PCOS (Zhao et al., 2010). Therefore, the
expression of BMP-15 and GDF-9 in both oocytes and CCs may
provide valuable support for the ability to regulate the follicular micro-
environment during the oocyte maturation process. Further study on
the role of BMP-15 or GDF-9 during follicle growth and oocyte
meiotic maturation will have important implications in understanding
those factors that regulate the mechanisms behind the pathogenesis
of PCOS, and help to improve IVM methods for oocytes from
women with PCOS.
Vascular endothelial growth factor family
Vascular endothelial growth factor (VEGF) is a homodimeric glyco-
protein belonging to the VEGF/platelet-derived growth factor family
(Artini et al., 2007). In the ovary, VEGF is expressed in GCs and
theca cells, but rarely in stroma cells (Artini et al., 2007) and is also
present in the FF (Artini et al., 1998; Van Blerkom, 2000; Stouffer
et al., 2001; Ocal et al., 2004). VEGF exerts its actions by binding to
one of three receptors, VEGFR-1/Flt-1, VEGFR-/KDR/Flk-1 or
VEGFR-3/Flt-4, functioning via the signal transduction system (De
Vries et al., 1992; Terman et al., 1992; Artini et al., 2007, 2009).
VEGF plays an important role in angiogenesis, follicular vascularization
and intrafollicular oxygenation, consequently impacting follicular matu-
ration, oocyte quality, fertilization and embryo developmental compe-
tence (Itskovitz et al., 1991; Van Blerkom et al., 1997; Agrawal et al.,
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Bokal et al., 2005).
In vitro culture studies show that VEGF stimulates the maturation of
bovine oocytes during IVM, resulting in increased rates of fertilization
and embryonic development (Luo et al., 2002; Bokal et al., 2005). In
NOW, decreased FF and serum VEGF levels are related to improved
ovarian response, consequently increasing the number of oocytes
retrieved, and improving the rates of fertilization and pregnancy; the
reverse has also been shown, as elevated FF VEGF levels are associated
with poor oocyte quality and decreased fertilization and pregnancy
rates, especially in older patients (Battaglia et al., 2000a, b; Ocal et al.,
2004; Artini et al., 2006, 2007). In women with PCOS, elevated FF
VEGFiscloselyassociatedwiththedevelopmentofovarianhyperstimu-
lation syndrome (Agrawal et al., 1998, 2002; Artini et al., 1998; Franks
etal.,2002).Furthermore,itiswellknownthatincreasedFFVEGFlevels
inPCOSpatientsisindicativeofimmatureoocytesandpoorfertilization
rates (Artini et al., 2006, 2009).
An opposing study concluded that follicles containing higher FF
VEGF concentrations provide better MII oocytes, compared with
those with lower FF VEGF concentrations (Bokal et al., 2004).
Among PCOS groups, reports suggest that prolonged hCG action
results in elevated FF VEGF, consequently increasing the number of
high-quality oocytes and embryos, as well as improving fertilization
rates (Bokal et al., 2005): the same researchers also demonstrated
that decreases in FF VEGF and E2 levels in PCOS women following
GnRH antagonist administration have detrimental effects on follicular
development, as compared with those women who were given ago-
nists, consequently reducing oocyte and embryo quality (Bokal et al.,
2009). Therefore, FF VEGF may serve as a dynamic indicator for the
evaluation of follicular maturity, subsequently predicting oocyte matur-
ity, fertilization success and embryo development in PCOS patients
(Bokal et al., 2005, 2009); however, further research is required to
uncover the true relationship between VEGF levels and subsequent
success in PCOS women.
Cytokine family
Cytokines encompass a large family of soluble polypeptide regulators
that are produced widely throughout the body by cells of diverse
embryological origin; the family comprises the interleukins (IL1  
35), leukemia inhibitory factor, tumor necrosis factor (TNF)a,
soluble Fas (sFas) and sFas ligand (sFasL) (TNFsubfamily). Within the
ovary, the action of cytokines may be autocrine or paracrine, but
not endocrine; they exist in the FF, suggesting their production by
GCs (Buyalos et al., 1992; Zolti et al., 1992; Jasper and Norman,
1995; Amato et al., 2003; Gallinelli et al., 2003), and have regulatory
functions in follicular maturation and subsequent embryonic develop-
ment (Coskun et al., 1998; Hsieh et al., 2005). In PCOS patients cyto-
kines are believed to play a role in ovarian hyperstimulation (Pellicer
et al., 1999) and hyperandrogenism (Escobar-Morreale et al., 2001);
however, these reports have been disputed (Gonzalez et al., 1999;
Deshpande et al., 2000; Amato et al., 2003).
Interleukins
ILs are a group of cytokines (secreted proteins/signaling molecules)
that are expressed by leukocytes (Wu et al., 2007a, b). Studies have
elucidated that ILs, namely IL-1, IL-2, IL-6, IL-8, IL-11, IL-12 and
other cytokines, play multiple roles in folliculogenesis, ovulation and
corpus luteum function (Barak et al., 1992; Naz and Butler, 1996;
Branisteanu et al., 1997; Gallinelli et al., 2003). FF IL-12 levels vary
within immature and pre-ovulatory follicles (Coskun et al., 1998);
the presence of FF IL-12 has been associated with fertilization failure
(Gazvani et al., 2000). An important study has demonstrated that
decreased FF IL-12 level and increased FF IL-13 level in PCOS patients
is correlated with a reduced rate of oocyte maturation, fertilization
and pregnancy, but this reduction did not reach statistical signiﬁcance
(Gallinelli et al., 2003).
Tumor necrosis factora
TNFa is a multifunctional hormone-like polypeptide, which is involved
in a wide range of physiological roles in regulating ovarian function,
exerting an inﬂuence on proliferation, differentiation, follicular matu-
ration, steroidogenesis and apoptosis (Le ´de ´e-Bataille et al., 2001;
van der Spuy and Dyer, 2004; Artini et al., 2007). In the ovary,
TNFa is expressed by the oocyte, theca cells, GCs and corpora
lutea (Artini et al., 2007). One IVM model, coupling porcine oocyte
co-incubation with high levels of TNFa, reported decreased oocyte
maturation and increased proportions of oocytes with abnormal chro-
mosomal alignment and cytoskeleton structure (Ma et al., 2010).
Alterations in FF TNFa levels are correlated with poor-quality
oocytes in women undergoing IVF (Cianci et al., 1996; Carlberg
et al., 2000; Lee et al., 2000), resulting in reduced rates of fertilization,
embryonic development and pregnancy outcome (Ma et al., 2010).
Furthermore, increased levels of FF TNFa in women with PCOS
are signiﬁcantly and inversely correlated to FF E2 levels, which
is again indicative of poor-quality oocytes and embryos
(Gallinelli et al., 2003; Amato et al., 2003; Wu et al., 2007a, b; Kim
et al., 2009).
Soluble Fas and sFas ligand
sFas and sFasL are transmembrane proteins belonging to the TNF
subfamily; sFas and sFasL proteins exert anti- and pro-apoptotic
functions, respectively. The binding of sFasL with its receptor
induces apoptosis, whereas sFas, acting as a functional antagonist,
binds with sFasL to inhibit sFasL-mediated apoptosis by preventing
death signal transduction (Ueno et al., 1999; Onalan et al., 2005).
sFas can be detected in human sera, oviduct ﬂuid and FF (Srivastava
et al., 1998; Onalan et al., 2005, 2006) and sFas levels in the FF are
positively correlated to oocyte maturity and survival in IVF patients
(Sarandakou et al., 2003). Some studies have demonstrated that
the sFas–sFasL system involves apoptosis of theca cells and GCs
in PCOS patients (Cataldo et al., 2000; Webber et al., 2003;
Onalan et al., 2005). Furthermore, these reports suggest that
reduced serum levels of sFas and DNA fragmentation in luteinized
GC are found in women with PCOS undergoing IVF treatment.
Patients with PCOS who are treated with metformin display anti-
apoptotic effects owing to elevated serum sFas levels and reduced
FF sFasL levels; GC DNA fragmentation was also reduced, thus
increasing implantation and clinical pregnancy rates (Onalan et al.,
2005). According to these data, one may speculate that abnormal-
ities in the sFas–sFasL system are indicative of PCOS pathogenesis,
further associating decreased oocyte quality, lower fertilization rates
and higher miscarriage rates with PCOS.
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Homocysteine
Homocysteine (Hcy) is a homologue of the amino acid cysteine, differ-
ing by an additional methylene group, and can be recycled into meth-
ionine or converted into cysteine in the presence of B-vitamins. Many
studies have established that elevated Hcy levels in serum and FF
are inversely associated with oocyte and embryo quality (Steegers-
Theunissen et al., 1992; Ebisch et al., 2006; Berker et al., 2009;
Naﬁye et al., 2010), resulting in decreased fertilization and pregnancy
rates, and increased miscarriage rates in PCOS patients undergoing
IVF treatment (Ludwig et al., 1999; Plachot et al., 2003; Yarali et al.,
2001; Loverro et al., 2002; Schacter et al., 2003; Heijnen et al.,
2006; Kaya et al., 2009; Berker et al., 2009; Naﬁye et al., 2010). Pre-
vious studies demonstrated that IVF patients who have higher E2 levels
in FF have improved rates of oocyte fertilization, cleavage and implan-
tation (Botero-Ruiz et al., 1984; Foong et al., 2005; Berker et al.,
2009). Furthermore, elevated levels of Hcy in FF and serum may sup-
press E2 synthesis, and consequently interfere with ovarian follicular
developmental competence, oocyte maturation and fertilization in
women with PCOS (Boxmeer et al., 2008; Berker et al., 2009). There-
fore, all of these results suggest that high levels of FF Hcy have a detri-
mental effect on oocyte and embryo quality, and may serve as a useful
indicator for potential success in PCOS patients undergoing assisted
reproduction.
Leptin
Leptin is a 16 kDa protein hormone that plays a key role in regulating
energy intake, energy expenditure and a balance between the two. It
has also served as a biomarker for body fat. In the ﬁeld of assisted
reproduction, leptin has been used to predict oocyte maturity and
embryo quality (Barroso et al., 1999; Georgios et al., 2005). High
leptin levels in the FF and serum are closely associated with decreased
oocyte maturity, poor fertilization and embryo quality, and lower preg-
nancy rates in PCOS patients (Mantzoros et al., 2000; Georgios et al.,
2005; Li et al., 2007). Some studies show that elevated leptin levels in
women with PCOS play an elementary role in the pathogenesis of
PCOS (Scarpace et al., 2000; Pasquali et al., 2006; Cervero et al.,
2006; Li et al., 2007). Others suggest that elevated leptin levels in
the ovary may block E2 production, disturbing follicular development
and oocyte maturation (Mantzoros et al., 2000). Hyperleptinemia,
or increased FF leptin, in PCOS patients may impair embryo quality
and pregnancy rates (Anifandis et al., 2005; De Placido et al., 2006,
Li et al., 2007). In contrast, other investigations have shown that FF
leptin is decreased in women with PCOS and is not a useful marker
for oocyte quality, fertilization or embryo development (Welt et al.,
2003; Plati et al., 2009). Hence, the involvement of leptin and its sig-
niﬁcance in the establishment of PCOS pathophysiology, especially its
impact on oocyte maturation competence, needs further clariﬁcation.
FF meiosis-activating sterol
FF meiosis-activating sterol (FF-MAS) is an endogenous signaling mol-
ecule and an intermediate in the cholesterol biosynthetic pathway,
which is present in FF (Byskov et al., 1999, 2002; Bokal et al., 2006;
Grondahl, 2008). Many IVM studies demonstrate that exposure to
FF-MAS can promote nuclear and cytoplasmic maturation of the
oocyte (Tsafriri and Motola, 2007) and improved fertilization and
early embryonic development in humans and other mammals (Cukur-
cam et al., 2003; Bivens et al., 2004; Faerge et al., 2006; Grondahl,
2008). Interestingly, reports show that FF-MAS enhances successful
IVM of oocytes retrieved from women with PCOS (Chian et al.,
2000; Grondahl, 2008). Furthermore, a leading report suggests that
the concentrations of FF-MAS signiﬁcantly increase during the
perio-ovulatory period, between 10–14 and 34–38 h after hCG
administration; this may be related to increased numbers of MII
stage oocytes retrieved from PCOS patients (Bokal et al., 2006).
This knowledge may prove to be useful in the implementation of
IVM protocols for PCOS patients.
Immunoreactive corticotrophin-releasing hormone, tissue inhibitor
of metalloproteinase-1 & 2 and visfatin
Immunoreactive corticotrophin-releasing hormone (IrCRH) is a
41-amino acid neuropetide (Vales et al., 1981), synthesized by theca
cells and/or the mature oocyte itself (Mastorakos et al., 1993,
1994). Study has found that decreased FF IrCRH levels are correlated
with oocyte dysfunction in women with PCOS (Mastorakos et al.,
1994). Other reports suggest that FF tissue inhibitor of metalloprotei-
nase (TIMP)-1 & 2 levels are signiﬁcantly lower in women with PCOS
than in NOW (Lahav-Bratz et al., 2003). In contrast, there was no
difference in basal production of TIMP-1 by cells in culture between
women with PCOS and NOW; however, matrix metalloproteinases-2
and 9 are signiﬁcantly increased in the FF of women with PCOS
(Shalev et al., 2001), suggesting an association with inappropriate
atresia. In a recent study, serum visfatin levels were signiﬁcantly
increased in women with PCOS, whereas FF visfatin levels do not
differ when compared with non-PCOS patients (Plati et al., 2009).
On the basis of these studies, it is difﬁcult to assign speciﬁc effects
to these factors, although their association to physiological or patho-
logical functions in PCOS is evident.
Renin
Renin (also known as angiotensinogenase) participates in the body’s
renin–angiotensin system. It is known that ovarian renin has an
impact on the developmental and fertilization competence of human
oocytes (Itskovitz et al., 1991; Van Blerkom et al., 1997; Loret de
Mola et al., 1999; Bokal et al., 2005). Investigations suggest that
decreased FF renin is related to increased rates of oocyte maturation
and fertilization, and better subsequent embryo quality (Bokal et al.,
2003, 2004, 2005).
Resistin
Resistin is a 12.5 kDa cyteine-rich protein hormone, synthesized by
adipose tissues (Seow et al., 2005). Recent studies demonstrate that
there are no signiﬁcant differences in either serum or FF resistin con-
centrations between PCOS patients and controls; these are also not
signiﬁcantly correlated with fertilization rates, implantation rates, clini-
cal pregnancy rates or early miscarriage rates in PCOS patients (Seow
et al., 2005). These data indicate that resistin is unlikely to be a useful
biomarker for oocyte developmental competence during IVF treat-
ment in PCOS women.
Oxidative stress
Reactive oxygen species (ROS) are involved in many physiological
functions and act as mediators in a variety of signaling pathways.
26 Qiao and FengDamage to biological systems caused by an excess of ROS is referred
to as OS (Gupta et al., 2009). In women with PCOS, data show that
increased FF ROS and decreased total antioxidant capacity and super-
oxide dismutase are closely associated with lower rates of oocyte
maturation and fertilization, poor embryo quality and decreased preg-
nancy rates (Sabatini et al., 2000; Ruder et al., 2008; Bausenwein et al.,
2010; Chattopadhayay et al., 2010). ROS degrade polyunsaturated
lipids, forming malondialdehyde (MDA) (Pryor and Stanley, 1975).
Elevated FF MDA levels are directly correlated with increased
numbers of immature oocytes retrieved, lower rates of fertilization
and embryonic development, and consequently, lower pregnancy
rates in PCOS patients (Yildirim et al., 2007; Berker et al., 2009).
Therefore, ROS may impair oocyte quality via alterations in the
balance of FFFs in the follicular microenvironment.
Concluding remarks
Patients with PCOS are typically characterized by production of an
increased numbers of oocytes during stimulation in an IVF cycle;
however, these women suffer from poor-quality oocytes and
embryos, lower fertilization, cleavage and implantation rates, and
higher miscarriage rates. A series of extra- and intra-ovarian factors
causing abnormalities during folliculogeneis, follicular growth and
oocyte meiotic maturation processes have been identiﬁed. Whether
these abnormalities have a direct inﬂuence on GC–oocyte inter-
actions and oocyte meiotic maturation, fertilization, embryonic devel-
opment and pregnancy, or whether the inﬂuences are through
circulating endocrine and local paracrine/autocrine mechanisms,
requires further clariﬁcation. Although many studies have been per-
formed in all aspects of endocrinology, genetics, metabolism and
reproduction in the etiology and pathology of PCOS, it remains a chal-
lenge for clinical and academic scientists alike to elucidate the molecu-
lar mechanisms involved; in particular, the oocyte’s developmental
competence and genetic disruption are undoubtedly important con-
siderations. Therefore, systematic screening for key intra-ovarian
factors which are related to PCOS (such as AMH, Hcy, growth
factors and cytokines) coupled with proper treatment for each
PCOS phenotype are essential issues in achieving success for PCOS
patients undergoing assisted reproduction, in an effort to effectively
improve oocyte maturation and developmental competence.
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